DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 21,772 shares of the medical device company’s stock after purchasing an additional 473 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in DexCom were worth $1,693,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Versant Capital Management Inc acquired a new position in DexCom during the fourth quarter valued at $25,000. Riverview Trust Co lifted its holdings in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom in the third quarter worth about $57,000. Covestor Ltd raised its position in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 265 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Oppenheimer reduced their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Leerink Partners dropped their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.29.

DexCom Stock Performance

NASDAQ DXCM opened at $88.75 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock’s fifty day moving average is $79.50 and its two-hundred day moving average is $77.35. The firm has a market capitalization of $34.67 billion, a P/E ratio of 53.14, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.